CN115197965A - Hpv疫苗 - Google Patents

Hpv疫苗 Download PDF

Info

Publication number
CN115197965A
CN115197965A CN202210614772.9A CN202210614772A CN115197965A CN 115197965 A CN115197965 A CN 115197965A CN 202210614772 A CN202210614772 A CN 202210614772A CN 115197965 A CN115197965 A CN 115197965A
Authority
CN
China
Prior art keywords
arenavirus
segment
viral vector
virus
hpv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210614772.9A
Other languages
English (en)
Chinese (zh)
Inventor
克劳斯·奥尔林格
托马斯·莫纳思
安德斯·莉亚
莎拉·施密特
厄休拉·贝尔卡
迈克尔·史温丁格
伊丽莎白·沃森
贝蒂娜·基埃弗曼
朱莉娅·辛特拉姆斯科格勒
格哈德·富尔曼
安德列亚斯·埃斯珀克
凯瑟琳·科恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hookipa Biotech GmbH
Original Assignee
Hookipa Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech GmbH filed Critical Hookipa Biotech GmbH
Publication of CN115197965A publication Critical patent/CN115197965A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202210614772.9A 2015-06-10 2016-06-09 Hpv疫苗 Pending CN115197965A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562173805P 2015-06-10 2015-06-10
US62/173,805 2015-06-10
US201562254410P 2015-11-12 2015-11-12
US62/254,410 2015-11-12
US201662331158P 2016-05-03 2016-05-03
US62/331,158 2016-05-03
CN201680046208.4A CN107921117B (zh) 2015-06-10 2016-06-09 Hpv疫苗
PCT/EP2016/063182 WO2016198531A2 (en) 2015-06-10 2016-06-09 Hpv vaccines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680046208.4A Division CN107921117B (zh) 2015-06-10 2016-06-09 Hpv疫苗

Publications (1)

Publication Number Publication Date
CN115197965A true CN115197965A (zh) 2022-10-18

Family

ID=56137292

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210614772.9A Pending CN115197965A (zh) 2015-06-10 2016-06-09 Hpv疫苗
CN201680046208.4A Active CN107921117B (zh) 2015-06-10 2016-06-09 Hpv疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680046208.4A Active CN107921117B (zh) 2015-06-10 2016-06-09 Hpv疫苗

Country Status (8)

Country Link
US (3) US10669315B2 (cg-RX-API-DMAC7.html)
EP (1) EP3307308A2 (cg-RX-API-DMAC7.html)
JP (2) JP7098330B2 (cg-RX-API-DMAC7.html)
CN (2) CN115197965A (cg-RX-API-DMAC7.html)
AU (2) AU2016274655B2 (cg-RX-API-DMAC7.html)
CA (1) CA2987155A1 (cg-RX-API-DMAC7.html)
HK (1) HK1246183A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016198531A2 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2604695T (lt) 2007-12-27 2022-12-12 Universität Zürich Replikacijos defektų turintys arenaviruso vektoriai
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP6818551B2 (ja) 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
CA2967720C (en) 2014-11-13 2024-01-02 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
AU2016274655B2 (en) 2015-06-10 2021-06-17 Hookipa Biotech Gmbh HPV vaccines
US20180289792A1 (en) 2015-10-22 2018-10-11 ModernaTX. Inc. Sexually transmitted disease vaccines
SG11201803474UA (en) 2015-11-04 2018-05-30 Hookipa Biotech Ag Vaccines against hepatitis b virus
CN108697775B (zh) 2015-11-12 2023-05-09 霍欧奇帕生物科技有限公司 作为癌症疫苗的沙粒病毒颗粒
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
CA3039356A1 (en) * 2016-11-04 2018-05-11 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
WO2018185307A1 (en) * 2017-04-07 2018-10-11 Hookipa Biotech Ag Arenavirus particles to treat solid tumors
CA3069821A1 (en) * 2017-07-14 2019-01-17 Oncorus, Inc. Encapsulated polynucleotides and methods of use
EP3461497A1 (en) 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
WO2019151760A1 (ko) * 2018-02-02 2019-08-08 주식회사 에스엘백시젠 신규 다가 hpv 백신 조성물
CN108424925A (zh) * 2018-03-07 2018-08-21 江苏润洁生物科技有限公司 一种治疗性hpv核酸疫苗
KR20210093285A (ko) * 2018-11-13 2021-07-27 온코루스, 인크. 캡슐화된 폴리뉴클레오티드 및 사용 방법
US20220001004A1 (en) * 2018-11-28 2022-01-06 The General Hospital Corporation T Cell-Directed Anti-Cancer Vaccines Against Commensal Viruses
JP7125760B2 (ja) * 2019-06-14 2022-08-25 国立研究開発法人理化学研究所 免疫系を賦活化する細胞および当該細胞を含む医薬組成物
EP3986455A1 (en) * 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
AU2020377504A1 (en) * 2019-11-07 2022-06-02 Universität Basel Arenaviruses as vectors
CA3160839A1 (en) * 2019-11-15 2022-05-09 Daiichi Sankyo Company, Limited Nucleic acid lipid particle vaccine encapsulating hpv mrna
US11744885B2 (en) 2020-05-14 2023-09-05 Inovio Pharmaceuticals, Inc. Vaccines for recurrent respiratory papillomatosis and methods of using the same
JP2023527083A (ja) 2020-05-29 2023-06-26 ホオキパ バイオテック ジーエムビーエイチ アレナウイルスベクターを使用するがんの治療方法
AU2022244100A1 (en) 2021-03-23 2023-10-19 Hookipa Biotech Gmbh Arenaviruses used in treatments of prostate cancer
CN115820696A (zh) * 2022-07-28 2023-03-21 怡道生物科技(苏州)有限公司 治疗性多价HPV mRNA疫苗及其制备方法
WO2025056782A1 (en) 2023-09-15 2025-03-20 Hookipa Biotech Gmbh Arenavirus formulations, methods and uses thereof
WO2025155938A1 (en) * 2024-01-18 2025-07-24 Aov Biopharma, Inc. Vaccine for prevention and treatment of human papilloma virus related cancer
WO2025191169A1 (en) * 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies
CN118344491B (zh) * 2024-05-03 2025-02-14 华中科技大学同济医学院附属同济医院 一种hpv16/18治疗性疫苗、制备方法和应用
CN118599010B (zh) * 2024-05-03 2025-06-27 武汉凯德基诺生物技术有限公司 一种hpv16/18/52治疗性疫苗、制备方法和应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012691A1 (fr) * 1998-08-27 2000-03-09 Fuso Pharmaceutical Industries, Ltd. Sequence d'acide nucleique utilisee pour potentialiser l'expression d'un gene utile et procede associe
CA2928263A1 (en) * 1999-04-06 2000-10-12 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
TW200631593A (en) * 2004-11-30 2006-09-16 Aeras Global Tb Vaccine Found Bacterial packaging strains useful for generation and production of recombinant double-stranded RNA nucleocapsids and uses thereof
CN101918565A (zh) * 2007-12-27 2010-12-15 苏黎士大学 复制缺陷型沙粒病毒载体
CN102002105A (zh) * 2009-09-03 2011-04-06 中国疾病预防控制中心病毒病预防控制所 Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途
WO2013151731A1 (en) * 2012-04-02 2013-10-10 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium for induction of cellular immune response
US20140243256A1 (en) * 2013-02-26 2014-08-28 The Administrators Of The Tulane Educational Fund Arenavirus inhibiting peptides and uses therefor
WO2016075250A1 (en) * 2014-11-13 2016-05-19 Université De Genève Tri-segmented arenaviruses as vaccine vectors
CN110719788A (zh) * 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒
WO2020255023A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
WO2004030636A2 (en) * 2002-10-03 2004-04-15 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
JP6219849B2 (ja) 2012-01-24 2017-10-25 サンフォード ヘルス 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド
WO2014140301A1 (en) 2013-03-15 2014-09-18 Université De Genève Anti-mycobacterial vaccines
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
JP6818551B2 (ja) 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
WO2015183895A1 (en) 2014-05-27 2015-12-03 University Of Rochester Novel arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
ES2746150T3 (es) 2014-09-22 2020-03-04 Univ Minnesota Sistema de genética inversa para el virus Pichindé y métodos de uso
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
AU2016274655B2 (en) 2015-06-10 2021-06-17 Hookipa Biotech Gmbh HPV vaccines
ES3021881T3 (en) 2015-10-23 2025-05-27 Pasteur Institut Recombinant mopeia virus and vaccine platform
SG11201803474UA (en) 2015-11-04 2018-05-30 Hookipa Biotech Ag Vaccines against hepatitis b virus
CN108697775B (zh) 2015-11-12 2023-05-09 霍欧奇帕生物科技有限公司 作为癌症疫苗的沙粒病毒颗粒
US10980877B2 (en) 2016-04-28 2021-04-20 The University Of Chicago Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen
CA3023599A1 (en) 2016-05-18 2017-11-23 Hookipa Biotech Gmbh Tri-segmented pichinde viruses as vaccine vectors
CA3039356A1 (en) 2016-11-04 2018-05-11 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
AU2020377504A1 (en) 2019-11-07 2022-06-02 Universität Basel Arenaviruses as vectors
JP2023527083A (ja) 2020-05-29 2023-06-26 ホオキパ バイオテック ジーエムビーエイチ アレナウイルスベクターを使用するがんの治療方法

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012691A1 (fr) * 1998-08-27 2000-03-09 Fuso Pharmaceutical Industries, Ltd. Sequence d'acide nucleique utilisee pour potentialiser l'expression d'un gene utile et procede associe
CA2928263A1 (en) * 1999-04-06 2000-10-12 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy
TW200631593A (en) * 2004-11-30 2006-09-16 Aeras Global Tb Vaccine Found Bacterial packaging strains useful for generation and production of recombinant double-stranded RNA nucleocapsids and uses thereof
CN101918565A (zh) * 2007-12-27 2010-12-15 苏黎士大学 复制缺陷型沙粒病毒载体
CN102002105A (zh) * 2009-09-03 2011-04-06 中国疾病预防控制中心病毒病预防控制所 Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途
WO2013151731A1 (en) * 2012-04-02 2013-10-10 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium for induction of cellular immune response
US20140243256A1 (en) * 2013-02-26 2014-08-28 The Administrators Of The Tulane Educational Fund Arenavirus inhibiting peptides and uses therefor
WO2016075250A1 (en) * 2014-11-13 2016-05-19 Université De Genève Tri-segmented arenaviruses as vaccine vectors
CN107223130A (zh) * 2014-11-13 2017-09-29 日内瓦大学 作为疫苗载体的三片段沙粒病毒
CN110719788A (zh) * 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒
WO2020255023A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BENSON YEE HIN CHENG等: "Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines", JOURNAL OF VIROLOGY, vol. 89, no. 14, 13 May 2015 (2015-05-13), pages 7373 - 7384, XP055239859, DOI: 10.1128/JVI.00307-15 *
LUKAS FLATZ等: "Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8 T cell immunity+", NATURE MEDICINE, vol. 16, 7 February 2010 (2010-02-07), pages 339 - 345, XP037922182, DOI: 10.1038/nm.2104 *
M.CRISTINA CASSETTI等: "Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes", VACCINE, vol. 22, no. 3, 31 January 2004 (2004-01-31), pages 520 - 527, XP004479374, DOI: 10.1016/j.vaccine.2003.07.003 *
SEBASTIEN E EMONET等: "Arenavirus reverse genetics: New approaches for the investigation of arenavirus biology and development of antiviral strategies", VIROLOGY, vol. 411, no. 2, 15 February 2011 (2011-02-15), pages 416 - 425, XP028185472, DOI: 10.1016/j.virol.2011.01.013 *
SEBASTIEN F. EMONET等: "Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest", PNAS, vol. 106, no. 9, 3 March 2009 (2009-03-03), pages 3473 - 3478, XP055226314, DOI: 10.1073/pnas.0900088106 *
周彤: "减毒曼哥病毒:重组活疫苗的新载体", 国外医学.预防.诊断.治疗用生物制品分册, no. 06, 15 December 1996 (1996-12-15), pages 275 *

Also Published As

Publication number Publication date
CA2987155A1 (en) 2016-12-15
CN107921117A (zh) 2018-04-17
JP2018518172A (ja) 2018-07-12
JP7098330B2 (ja) 2022-07-11
AU2021232660B2 (en) 2025-02-27
US20180179257A1 (en) 2018-06-28
WO2016198531A3 (en) 2017-01-19
US11407790B2 (en) 2022-08-09
US20210024584A1 (en) 2021-01-28
AU2016274655A1 (en) 2017-12-21
US20230086859A1 (en) 2023-03-23
US10669315B2 (en) 2020-06-02
HK1246183A1 (zh) 2018-09-07
AU2016274655B2 (en) 2021-06-17
EP3307308A2 (en) 2018-04-18
CN107921117B (zh) 2022-06-07
AU2021232660A1 (en) 2021-10-07
JP2022160401A (ja) 2022-10-19
WO2016198531A2 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
AU2021232660B2 (en) HPV vaccines
AU2014359276B2 (en) CMV vaccines
AU2016348675B2 (en) Vaccines against Hepatitis B virus
US7318928B2 (en) Molecular vaccine linking intercellular spreading protein to an antigen
RU2644201C2 (ru) Вакцины против hpv
CN110719788A (zh) 治疗实体瘤的沙粒病毒颗粒
JP2004500047A (ja) キメラ免疫原性組成物およびこれらをコードする核酸
US20070166328A1 (en) Genetic immunization against cervical carcinoma
KR102715320B1 (ko) 신형 hpv 치료용 핵산 백신
JP2019514988A (ja) 組合せプライム：ブースト療法
Bissa et al. A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers
US20080260765A1 (en) HPV DNA Vaccines and Methods of Use Thereof
HK40082300A (en) Hpv vaccines
HK1263252A1 (en) Vaccines against hepatitis b virus
HK1263252B (en) Vaccines against hepatitis b virus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082300

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221018